NASDAQ:REGN - Regeneron Stock Price, Price Target & More

$316.99 -4.40 (-1.37 %)

(As of 04/19/2018 03:24 PM ET)

Previous Close$321.39

Today's Range$315.60 - $322.69

52-Week Range$313.53 - $543.55

Volume326,301 shs

Average Volume925,652 shs

Market Capitalization$34.75 billion

P/E Ratio23.64

Dividend YieldN/A

Beta1.46

About Regeneron (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:REGN

CUSIP75886F10

Webwww.regeneron.com

Phone914-847-7000

Debt

Debt-to-Equity Ratio0.11%

Current Ratio3.82%

Quick Ratio3.18%

Price-To-Earnings

Trailing P/E Ratio23.64

Forward P/E Ratio16.51

P/E Growth1.05

Sales & Book Value

Annual Sales$5.87 billion

Price / Sales5.81

Cash Flow$15.5846 per share

Price / Cash20.34

Book Value$57.09 per share

Price / Book5.55

Profitability

EPS (Most Recent Fiscal Year)$13.41

Net Income$1.20 billion

Net Margins20.41%

Return on Equity28.48%

Return on Assets19.26%

Miscellaneous

Employees6,200

Outstanding Shares107,700,000

How to Become a New Pot Stock Millionaire

Regeneron (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron's stock symbol?

Regeneron trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron's earnings last quarter?

Regeneron (NASDAQ:REGN) posted its quarterly earnings data on Thursday, February, 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.18 by $1.05. The biopharmaceutical company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. The company's revenue was up 28.9% compared to the same quarter last year. During the same period last year, the firm posted $3.04 earnings per share. View Regeneron's Earnings History.

When is Regeneron's next earnings date?

Regeneron is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Regeneron.

What price target have analysts set for REGN?

25 brokerages have issued 1-year price objectives for Regeneron's stock. Their forecasts range from $356.00 to $593.00. On average, they anticipate Regeneron's stock price to reach $454.9167 in the next year. View Analyst Ratings for Regeneron.

What are Wall Street analysts saying about Regeneron stock?

Here are some recent quotes from research analysts about Regeneron stock:

1. According to Zacks Investment Research, "Regeneron’s top-line continues to be driven by strong Eylea sales. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales in 2018. The action date set by the FDA is Aug 11, 2018. The approval of new drugs like Kevzara and Dupixent provides a significant boost. Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. Kevzara is also expected to pick up further. A potential approval of PD-1 antibody cemiplimab, in advanced cutaneous squamous cell carcinoma will further boost prospects. However, shares of the company have underperformed the industry in the last 12 months. Sales of Praluent have failed to impress to date." (4/11/2018)
2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)

Who are some of Regeneron's key competitors?

Some companies that are related to Regeneron include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO) and Alnylam Pharmaceuticals (ALNY).

Who are Regeneron's key executives?

Regeneron's management team includes the folowing people:

Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)
Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)
Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)
Dr. Neil Stahl Ph.D., Exec. VP of R&D (Age 61)
Mr. Robert J. Terifay, Exec. VP of Commercial(Leave of Absence) (Age 58)

Has Regeneron been receiving favorable news coverage?

Press coverage about REGN stock has trended somewhat negative on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron earned a media sentiment score of -0.03 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.01 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Regeneron?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron's stock price today?

One share of REGN stock can currently be purchased for approximately $317.26.

How big of a company is Regeneron?

Regeneron has a market capitalization of $34.75 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron employs 6,200 workers across the globe.

How can I contact Regeneron?

Regeneron's mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

MarketBeat Community Rating for Regeneron (REGN)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		1,035 (Vote Outperform)
Underperform Votes:		835 (Vote Underperform)
Total Votes:		1,870

MarketBeat's community ratings are surveys of what our community members think about Regeneron and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Regeneron (NASDAQ:REGN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

25 Wall Street analysts have issued ratings and price targets for Regeneron in the last 12 months. Their average twelve-month price target is $454.9167, suggesting that the stock has a possible upside of 43.51%. The high price target for REGN is $593.00 and the low price target for REGN is $356.00. There are currently 1 sell rating, 16 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.28	2.36	2.38	2.37
Ratings Breakdown:	1 Sell Rating(s) 16 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 14 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 14 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 13 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$454.9167	$455.75	$472.50	$490.5833
Price Target Upside:	43.51% upside	32.27% upside	25.50% upside	11.26% upside

Regeneron (NASDAQ:REGN) Consensus Price Target History

Price Target History for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Credit Suisse Group	Lower Price Target	Buy	$440.00 -> $420.00	Low
4/9/2018	Raymond James	Reiterated Rating	Outperform -> Market Perform		Low
4/9/2018	UBS	Downgrade	Outperform -> Market Perform		Low
3/13/2018	BTIG Research	Reiterated Rating	Hold		Medium
3/13/2018	Deutsche Bank	Set Price Target	Hold	$367.00	Medium
2/21/2018	Canaccord Genuity	Downgrade	Buy -> Hold	$522.00 -> $356.00	Medium
2/9/2018	SunTrust Banks	Set Price Target	Hold	$430.00	Low
2/9/2018	Morgan Stanley	Boost Price Target	Equal Weight -> Equal Weight	$401.00 -> $415.00	High
2/9/2018	Leerink Swann	Lower Price Target	Outperform -> Outperform	$568.00 -> $502.00	High
2/9/2018	Robert W. Baird	Upgrade	Neutral -> Outperform		High
2/9/2018	Guggenheim	Set Price Target	Buy	$530.00	High
2/8/2018	Jefferies Group	Reiterated Rating	Neutral -> Hold	$380.00	High
2/8/2018	BMO Capital Markets	Boost Price Target	Market Perform -> Market Perform	$398.00 -> $444.00	Low
2/7/2018	Cowen	Reiterated Rating	Hold	$450.00	High
1/24/2018	JPMorgan Chase	Boost Price Target	Neutral -> Neutral	$455.00 -> $457.00	Low
1/9/2018	Citigroup	Reiterated Rating	Neutral -> Neutral	$380.00 -> $388.00	High
12/28/2017	Argus	Lower Price Target	Positive -> Buy	$540.00 -> $470.00	Low
12/14/2017	Royal Bank of Canada	Reiterated Rating	Hold	$430.00	Low
11/16/2017	Evercore ISI	Lower Price Target	Outperform	$605.00 -> $445.00	N/A
11/13/2017	Piper Jaffray	Reiterated Rating	Buy	$540.00	N/A
10/20/2017	Barclays	Downgrade	Equal Weight -> Underweight	$450.00 -> $395.00	N/A
9/27/2017	Oppenheimer	Reiterated Rating	Hold		Low
8/9/2017	Goldman Sachs	Reiterated Rating	Neutral	$469.00 -> $472.00	Low
7/21/2017	Bank of America	Reiterated Rating	Buy	$589.00 -> $593.00	Low
6/26/2017	Sanford C. Bernstein	Downgrade	Outperform -> Market Perform	$410.00 -> $480.00	Low
3/17/2017	CIBC	Initiated Coverage	Market Perform -> Market Perform		Low
1/10/2017	Wells Fargo	Reiterated Rating	Market Perform		N/A
1/6/2017	Chardan Capital	Lower Price Target	Neutral	$350.00 -> $345.00	N/A
10/28/2016	Roth Capital	Set Price Target	Buy	$520.00	N/A
8/5/2016	Brean Capital	Reiterated Rating	Buy	$489.00	N/A

(Data available from 4/19/2016 forward)

Regeneron (NASDAQ:REGN) Earnings History and Estimates Chart

Earnings by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Earnings Estimates

Current Year EPS Consensus Estimate: $19.2 EPS
Next Year EPS Consensus Estimate: $20.07 EPS

Regeneron (NASDAQ REGN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$4.17					N/A
2/8/2018	Q4 2017	$4.18	$5.23	$1.5048 billion	$1.5820 billion	View	N/A
11/8/2017	Q3 2017	$3.83	$3.99	$1.4498 billion	$1.5010 billion	View	N/A
8/3/2017	Q2 2017	$2.67	$4.17	$1.3572 billion	$1.47 billion	View	Listen
5/4/2017	Q1 2017	$2.50	$2.92	$1.2992 billion	$1.3190 billion	View	Listen
2/9/2017	Q4 2016	$3.03	$3.04	$1.30 billion	$1.23 billion	View	Listen
11/4/2016	Q316	$2.73	$3.13	$1.29 billion	$1.22 billion	View	N/A
8/4/2016	Q216	$2.65	$2.82	$1.24 billion	$1.21 billion	View	N/A
5/5/2016	Q116	$2.58	$2.57	$1.18 billion	$1.20 billion	View	N/A
2/9/2016	Q415	$3.40	$2.83	$1.17 billion	$1.10 billion	View	Listen
11/4/2015	Q315	$2.62	$3.47	$1.05 billion	$1.14 billion	View	Listen
8/4/2015	Q215	$2.77	$2.89	$887.03 million	$999.00 million	View	Listen
5/7/2015	Q115	$2.50	$2.88	$820.30 million	$870.00 million	View	N/A
2/10/2015	Q414	$2.78	$2.79	$775.42 million	$802.00 million	View	N/A
11/4/2014	Q314	$2.57	$2.52	$733.04 million	$726.00 million	View	N/A
8/5/2014	Q214	$2.30	$2.47	$647.99 million	$666.00 million	View	N/A
5/8/2014	Q114	$0.94	$0.58	$609.04 million	$626.00 million	View	N/A
2/11/2014	Q413	$0.97	$2.24	$579.17 million	$610.00 million	View	N/A
11/5/2013	Q313	$0.92	$2.40	$501.93 million	$597.00 million	View	N/A
8/6/2013	Q2 2013	$0.92	$1.73	$470.63 million	$458.00 million	View	N/A
5/3/2013	Q1 2013	$1.46	$1.78	$424.26 million	$440.00 million	View	N/A
2/14/2013	Q4 2012	$1.11	$1.47	$392.64 million	$415.00 million	View	N/A
10/24/2012		$1.14	$1.89			View	N/A
7/25/2012		$0.45	$0.90			View	N/A
4/26/2012		($0.33)	$0.37			View	N/A
2/13/2012		($0.60)	($0.37)			View	N/A
10/27/2011	Q3 2011	($0.75)	($0.68)			View	N/A
7/28/2011		($0.40)	($0.69)			View	N/A
5/3/2011	Q1 2011	($0.38)	($0.49)			View	N/A
2/17/2011	Q4 2010	($0.32)	($0.17)			View	N/A
10/28/2010	Q3 2010	($0.34)	($0.41)			View	N/A
7/28/2010	Q2 2010	($0.38)	($0.31)			View	N/A
4/29/2010	Q1 2010	($0.49)	($0.38)			View	N/A
2/18/2010	Q4 2009	($0.34)	($0.46)			View	N/A
11/3/2009	Q3 2009	($0.23)	($0.01)			View	N/A
8/4/2009	Q2 2009	($0.28)	($0.19)			View	N/A
4/30/2009	Q1 2009	($0.29)	($0.22)			View	N/A
2/26/2009	Q4 2008	($0.30)	($0.40)			View	N/A
11/4/2008	Q3 2008	($0.32)	($0.27)			View	N/A
7/31/2008	Q2 2008	($0.35)	($0.22)			View	N/A
5/1/2008	Q1 2008	($0.34)	($0.15)			View	N/A
2/27/2008	Q4 2007	($0.46)	($0.19)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Regeneron (NASDAQ:REGN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Regeneron (NASDAQ REGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 66.40%

Insider Trading History for Regeneron (NASDAQ:REGN)

Institutional Ownership by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ REGN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2018	Joseph L Goldstein	Director	Sell	2,000	$350.02	$700,040.00	14,000
3/14/2018	Joseph L Goldstein	Director	Sell	2,000	$340.00	$680,000.00	14,000
2/9/2018	Joseph L Goldstein	Director	Sell	1,000	$325.60	$325,600.00
10/5/2017	Michael S Brown	Director	Sell	1,500	$475.00	$712,500.00
9/29/2017	Charles A Baker	Director	Sell	2,000	$450.00	$900,000.00	11,000
9/6/2017	Robert E Landry	SVP	Sell	663	$498.60	$330,571.80	10,099
9/5/2017	Robert E Landry	CFO	Sell	189	$501.06	$94,700.34	10,099
8/31/2017	Robert E Landry	SVP	Sell	427	$493.43	$210,694.61	9,099
8/25/2017	Sanofi	Major Shareholder	Buy	72,378	$481.36	$34,839,874.08
8/24/2017	Sanofi	Major Shareholder	Buy	166,415	$480.93	$80,033,965.95
8/23/2017	Robert E Landry	SVP	Sell	468	$476.45	$222,978.60	9,099
8/22/2017	P Roy Vagelos	Chairman	Sell	56,213	$474.48	$26,671,944.24	363,638
8/18/2017	P Roy Vagelos	Chairman	Sell	15,191	$470.15	$7,142,048.65	329,543
8/17/2017	P Roy Vagelos	Chairman	Sell	1,305	$470.00	$613,350.00	329,543
8/16/2017	P Roy Vagelos	Chairman	Sell	10,986	$470.17	$5,165,287.62	329,543
8/8/2017	Robert E Landry	SVP	Sell	526	$472.19	$248,371.94	9,099
6/22/2017	Michael S Aberman	SVP	Sell	2,269	$532.42	$1,208,060.98	9,193
6/22/2017	Neil Stahl	EVP	Sell	8,306	$532.55	$4,423,360.30	43,950
6/20/2017	Michael S Brown	Director	Sell	3,000	$500.00	$1,500,000.00	3,000
6/16/2017	Robert J Terifay	EVP	Sell	21,147	$468.19	$9,900,813.93	72,043
6/15/2017	Neil Stahl	EVP	Sell	8,567	$468.45	$4,013,211.15	44,245
6/9/2017	Joseph L Goldstein	Director	Sell	1,000	$482.55	$482,550.00	14,000
6/2/2017	Neil Stahl	EVP	Sell	2,812	$479.49	$1,348,325.88	28,477
6/2/2017	Sanofi	Major Shareholder	Buy	136,050	$478.17	$65,055,028.50
5/25/2017	P Roy Vagelos	Chairman	Sell	9,295	$458.14	$4,258,411.30	414,156
5/12/2017	Michael S Brown	Director	Sell	3,000	$450.00	$1,350,000.00	3,000
3/29/2017	Michael S Brown	Director	Sell	1,000	$400.00	$400,000.00	1,000
1/11/2017	Sanofi	Major Shareholder	Buy	87,298	$369.71	$32,274,943.58
12/12/2016	Charles A Baker	Director	Sell	3,000	$392.02	$1,176,060.00	12,000
11/15/2016	Arthur F Ryan	Director	Sell	2,000	$429.34	$858,680.00	36,500
11/14/2016	Joseph L Goldstein	Director	Sell	2,125	$450.00	$956,250.00	15,125
7/29/2016	Joseph L Goldstein	Director	Sell	2,125	$425.00	$903,125.00	15,125
6/14/2016	Sanofi	Major Shareholder	Buy	64,731	$363.86	$23,553,021.66
5/24/2016	Arthur F Ryan	Director	Sell	1,000	$396.64	$396,640.00	40,500
5/18/2016	Plew Daniel P Van	EVP	Sell	4,413	$385.77	$1,702,403.01	11,381
4/6/2016	Joseph L Goldstein	Director	Sell	2,000	$425.00	$850,000.00	13,000
3/21/2016	Joseph L Goldstein	Director	Sell	2,000	$375.00	$750,000.00	16,000
2/17/2016	Sanofi	Major Shareholder	Buy	161,157	$392.46	$63,247,676.22
1/12/2016	Sanofi	Major Shareholder	Buy	83,938	$465.04	$39,034,527.52
12/29/2015	Douglas S. Mccorkle	VP	Sell	3,954	$552.08	$2,182,924.32	6,866
12/10/2015	Michael S. Brown	Director	Sell	3,000	$546.45	$1,639,350.00
12/2/2015	George Yancopoulos	insider	Sell	43,348	$549.03	$23,799,352.44	500,000
11/18/2015	P Roy Vagelos	Chairman	Sell	17,240	$587.90	$10,135,396.00	332,880
11/10/2015	Plew Daniel P. Van	SVP	Sell	5,123	$554.85	$2,842,496.55
11/9/2015	Neil Stahl	EVP	Sell	42,101	$561.45	$23,637,606.45	22,029
11/3/2015	P Roy Vagelos	Chairman	Sell	17,242	$580.19	$10,003,635.98	351,851
11/2/2015	George Yancopoulos	insider	Sell	43,348	$571.61	$24,778,150.28	543,348
10/6/2015	Sanofi	Major Shareholder	Buy	80,538	$459.71	$37,024,123.98
9/23/2015	Sanofi	Major Shareholder	Buy	147,209	$534.67	$78,708,236.03
9/21/2015	Michael S. Brown	Director	Sell	3,000	$551.55	$1,654,650.00
9/17/2015	Charles A. Baker	Director	Sell	5,000	$550.00	$2,750,000.00	9,000
8/14/2015	Peter Powchik	SVP	Sell	23,485	$573.38	$13,465,829.30
7/15/2015	Joseph L Goldstein	Director	Sell	2,000	$550.00	$1,100,000.00
6/22/2015	Joseph L Goldstein	Director	Sell	2,000	$526.85	$1,053,700.00
5/27/2015	Robert Alexander Ingram	Director	Sell	1,379	$513.39	$707,964.81
5/26/2015	Plew Daniel P Van	SVP	Sell	18,370	$508.42	$9,339,675.40
5/22/2015	Douglas S Mccorkle	VP	Sell	13,000	$515.60	$6,702,800.00
5/22/2015	Joseph L Goldstein	Director	Sell	4,000	$514.28	$2,057,120.00
5/15/2015	Michael S Brown	Director	Sell	5,000	$495.00	$2,475,000.00
3/25/2015	Charles A Baker	Director	Sell	5,000	$454.96	$2,274,800.00
3/24/2015	Michael S Aberman	SVP	Sell	4,843	$478.99	$2,319,748.57
3/18/2015	Michael S Aberman	SVP	Sell	3,442	$465.00	$1,600,530.00
3/17/2015	Robert J Terifay	SVP	Sell	10,993	$451.01	$4,957,952.93
3/16/2015	Joseph J Larosa	SVP	Sell	18,311	$450.00	$8,239,950.00
2/27/2015	Douglas S Mccorkle	VP	Sell	3,000	$416.24	$1,248,720.00
2/26/2015	Marc Tessier-Lavigne	Director	Sell	3,000	$421.95	$1,265,850.00
2/24/2015	Robert J Terifay	SVP	Sell	11,173	$423.67	$4,733,664.91
2/23/2015	Plew Daniel P Van	SVP	Sell	9,431	$427.82	$4,034,770.42
2/20/2015	Joseph L Goldstein	Director	Sell	5,000	$423.65	$2,118,250.00
2/17/2015	Michael S Aberman	SVP	Sell	3,692	$404.46	$1,493,266.32
1/2/2015	Leonard S Schleifer	CEO	Sell	1,500	$410.58	$615,870.00
1/2/2015	Peter Powchik	SVP	Sell	10,822	$414.08	$4,481,173.76
12/24/2014	Sanofi	Major Shareholder	Buy	201,459	$393.21	$79,215,693.39
12/16/2014	Douglas S Mccorkle	VP	Sell	8,486	$410.15	$3,480,532.90
11/24/2014	Alfred G Gilman	Director	Sell	40,000	$408.44	$16,337,600.00
11/24/2014	Neil Stahl	SVP	Sell	5,307	$412.93	$2,191,419.51
11/18/2014	Robert J Terifay	SVP	Sell	22,362	$405.79	$9,074,275.98
11/13/2014	Plew Daniel P Van	SVP	Sell	8,575	$399.34	$3,424,340.50
11/12/2014	Joseph L Goldstein	Director	Sell	5,000	$398.31	$1,991,550.00
11/12/2014	Leonard S Schleifer	CEO	Sell	45,817	$400.30	$18,340,545.10
10/28/2014	Leonard S Schleifer	CEO	Sell	69,112	$404.01	$27,921,939.12
10/24/2014	Michael S Brown	Director	Sell	5,000	$399.00	$1,995,000.00
10/24/2014	Murray A Goldberg	SVP	Sell	26,788	$400.70	$10,733,951.60
9/16/2014	Sanofi	Major Shareholder	Buy	31,717	$349.26	$11,077,479.42
9/15/2014	Sanofi	Major Shareholder	Buy	140,632	$345.15	$48,539,134.80
9/10/2014	P Roy Vagelos	Chairman	Sell	10,328	$350.07	$3,615,522.96
8/27/2014	Joseph L Goldstein	Director	Sell	2,000	$350.31	$700,620.00
8/19/2014	Michael S Aberman	VP	Sell	3,611	$350.00	$1,263,850.00
8/18/2014	Douglas S Mccorkle	VP	Sell	5,875	$353.00	$2,073,875.00
8/15/2014	Michael S Brown	Director	Sell	3,000	$349.20	$1,047,600.00
8/14/2014	Joseph L Goldstein	Director	Sell	2,000	$347.65	$695,300.00
8/13/2014	P Roy Vagelos	Chairman	Sell	8,028	$340.01	$2,729,600.28
8/11/2014	Neil Stahl	SVP	Sell	11,646	$339.96	$3,959,174.16
8/11/2014	P Roy Vagelos	Chairman	Sell	11,972	$340.11	$4,071,796.92
8/8/2014	Neil Stahl	SVP	Sell	2,841	$340.60	$967,644.60
8/7/2014	Plew Daniel P Van	SVP	Sell	6,806	$338.37	$2,302,946.22
8/6/2014	Joseph L Goldstein	Director	Sell	2,000	$331.20	$662,400.00
7/15/2014	Sanofi	Major Shareholder	Buy	129,100	$314.92	$40,656,172.00
7/14/2014	Sanofi	Major Shareholder	Buy	300,000	$316.80	$95,040,000.00
7/10/2014	Sanofi	Major Shareholder	Buy	175,000	$311.08	$54,439,000.00
7/9/2014	Sanofi	Major Shareholder	Buy	348,000	$309.76	$107,796,480.00
7/7/2014	Sanofi	Major Shareholder	Buy	356,700	$312.37	$111,422,379.00
7/2/2014	Sanofi	Major Shareholder	Buy	212,400	$307.25	$65,259,900.00
7/1/2014	Sanofi	Major Shareholder	Buy	212,400	$300.20	$63,762,480.00
6/30/2014	Sanofi	Major Shareholder	Buy	262,400	$281.17	$73,779,008.00
5/23/2014	Plew Daniel Van	SVP	Sell	5,369	$295.93	$1,588,848.17	15,441
5/19/2014	Sanofi	major shareholder	Buy	190,751	$300.04	$57,232,930.04
3/28/2014	Sanofi	major shareholder	Buy	306,945	$306.73	$94,149,239.85
3/27/2014	Sanofi	major shareholder	Buy	306,945	$311.01	$95,462,964.45
3/24/2014	Charles Baker	Director	Sell	15,000	$302.67	$4,540,050.00	9,000
3/24/2014	Sanofi	major shareholder	Buy	306,945	$307.91	$94,511,434.95
3/21/2014	Sanofi	major shareholder	Buy	305,115	$321.22	$98,009,040.30
3/20/2014	Sanofi	major shareholder	Buy	67,703	$328.33	$22,228,925.99
3/17/2014	Michael Brown	Director	Sell	2,000	$334.29	$668,580.00	14,662
3/17/2014	Sanofi	major shareholder	Buy	115,711	$328.46	$38,006,435.06
3/12/2014	Sanofi	major shareholder	Buy	220,995	$334.69	$73,964,816.55
3/11/2014	Sanofi	major shareholder	Buy	380,532	$330.41	$125,731,578.12
3/7/2014	Sanofi	major shareholder	Buy	150,277	$328.72	$49,399,055.44
3/3/2014	Sanofi	major shareholder	Buy	251,594	$338.12	$85,068,963.28
2/27/2014	Michael Brown	Director	Sell	1,000	$335.00	$335,000.00	14,662
2/25/2014	Joseph Goldstein	Director	Sell	1,000	$338.86	$338,860.00
2/25/2014	Murray Goldberg	SVP	Sell	11,871	$339.55	$4,030,798.05	63,102
2/21/2014	Alfred Gilman	Director	Sell	5,000	$340.00	$1,700,000.00
2/21/2014	Murray Goldberg	SVP	Sell	21,258	$336.51	$7,153,529.58	63,102
2/20/2014	Joseph Goldstein	Director	Sell	1,000	$326.99	$326,990.00	1,000
2/18/2014	Michael Aberman	VP	Sell	3,648	$331.42	$1,209,020.16	15,600
2/18/2014	Robert Terifay	SVP	Sell	12,865	$332.68	$4,279,928.20	20,029
2/13/2014	Neil Stahl	SVP	Sell	22,612	$318.82	$7,209,157.84	24,391
2/12/2014	George Yancopoulos	Insider	Sell	88,987	$320.33	$28,505,205.71	1,068,343
2/12/2014	Joseph Goldstein	Director	Sell	1,000	$320.62	$320,620.00	2,000
2/11/2014	Alfred Gilman	Director	Sell	5,000	$320.00	$1,600,000.00
2/11/2014	Douglas Mccorkle	VP	Sell	5,819	$325.00	$1,891,175.00
2/11/2014	P Roy Vagelos	Chairman	Sell	11,475	$325.10	$3,730,522.50	69,960
2/7/2014	Sanofi	major shareholder	Buy	168,511	$286.78	$48,325,584.58
2/5/2014	Sanofi	major shareholder	Buy	397,264	$284.12	$112,870,647.68
2/3/2014	Sanofi	major shareholder	Buy	208,972	$283.78	$59,302,074.16
1/28/2014	Sanofi	major shareholder	Buy	157,920	$275.90	$43,570,128.00
1/14/2014	Alfred Gilman	Director	Sell	5,000	$300.00	$1,500,000.00
1/14/2014	Douglas Mccorkle	VP	Sell	4,000	$290.00	$1,160,000.00
1/2/2014	Peter Powchik	SVP	Sell	20,668	$274.77	$5,678,946.36	25,447
12/20/2013	Peter Powchik	SVP	Sell	9,133	$270.21	$2,467,827.93	20,742
11/26/2013	George Sing	Director	Sell	10,000	$295.00	$2,950,000.00	112,772
11/6/2013	Joseph Goldstein	Director	Sell	1,000	$300.74	$300,740.00	3,000
9/19/2013	Leonard Schleifer	CEO	Sell	102,949	$302.67	$31,159,573.83	42,087
9/19/2013	P Roy Vagelos	Chairman	Sell	145,356	$302.86	$44,022,518.16	65,759
9/18/2013	Plew Daniel Van	SVP	Sell	23,977	$303.17	$7,269,107.09	10,736
9/18/2013	William Roberts	VP	Sell	15,000	$304.00	$4,560,000.00	16,644
9/9/2013	Leonard S Schleifer	CEO	Sell	5,000	$275.47	$1,377,350.00
8/23/2013	Joseph Goldstein	Director	Sell	1,000	$238.29	$238,290.00	4,000
6/10/2013	Charles A Baker	Director	Sell	15,000	$251.84	$3,777,600.00
5/31/2013	Arthur F Ryan	Director	Sell	2,500	$249.55	$623,875.00
5/28/2013	Joseph L Goldstein	Director	Sell	4,000	$252.20	$1,008,800.00
5/21/2013	Murray A Goldberg	CFO	Sell	66,835	$259.74	$17,359,722.90
5/17/2013	Michael S Brown	Director	Sell	15,000	$275.19	$4,127,850.00
5/14/2013	Michael S Aberman	VP	Sell	5,529	$279.61	$1,545,963.69
5/13/2013	Neil Stahl	SVP	Sell	23,038	$276.88	$6,378,761.44
5/10/2013	George L Sing	Director	Sell	5,000	$270.00	$1,350,000.00
5/8/2013	Robert J Terifay	SVP	Sell	8,231	$261.23	$2,150,184.13
5/6/2013	P Roy Vagelos	Chairman	Sell	12,018	$263.15	$3,162,536.70
11/27/2012	P Roy Vagelos	Chairman	Sell	64,753	$175.22	$11,346,020.66
11/26/2012	Charles A Baker	Director	Sell	15,000	$173.87	$2,608,050.00
11/14/2012	Michael S Brown	Director	Sell	7,000	$147.03	$1,029,210.00
11/1/2012	Arthur F Ryan	Director	Sell	10,000	$145.57	$1,455,700.00
9/6/2012	Charles A Baker	Director	Sell	15,000	$150.00	$2,250,000.00
8/23/2012	George L Sing	Director	Sell	10,000	$140.50	$1,405,000.00

(Data available from 1/1/2013 forward)

Regeneron (NASDAQ REGN) News Headlines

Source:

Date	Headline
	Analysts’ Recommendations for Exelixis in April 2018 finance.yahoo.com - April 19 at 10:28 AM
	BidaskClub Lowers Regeneron (REGN) to Sell www.americanbankingnews.com - April 18 at 9:51 AM
	Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest? 247wallst.com - April 17 at 3:55 PM
	Regeneron (REGN) Price Target Cut to $420.00 www.americanbankingnews.com - April 17 at 1:29 PM
	Regeneron (REGN) Rating Lowered to Underperform at Robert W. Baird www.americanbankingnews.com - April 14 at 4:13 PM
	Regeneron (REGN) Given "Overweight" Rating at Piper Jaffray www.americanbankingnews.com - April 14 at 3:07 PM
	Regeneron (REGN) Stock Rating Reaffirmed by JPMorgan Chase www.americanbankingnews.com - April 13 at 5:29 PM
	BMO Capital Markets Reiterates $491.00 Price Target for Regeneron (REGN) www.americanbankingnews.com - April 13 at 10:53 AM
	Oakmark fund manager talks his Q1 buys finance.yahoo.com - April 12 at 3:51 PM
	3 Biotech Stocks Analysts Have Been Too Bullish On finance.yahoo.com - April 12 at 3:51 PM
	Exploring the Growth of Regeneron’s Praluent finance.yahoo.com - April 12 at 3:51 PM
	Free Research Reports on These Biotech Stocks -- Regeneron Pharma, Sangamo Therapeutics, Seattle Genetics, and ... www.prnewswire.com - April 12 at 11:20 AM
	Regeneron (REGN) Receives "Outperform" Rating from Leerink Swann www.americanbankingnews.com - April 11 at 11:52 PM
	Regeneron (REGN) Earns "Neutral" Rating from Goldman Sachs www.americanbankingnews.com - April 11 at 11:52 PM
	Regeneron (REGN) Given Hold Rating at JPMorgan Chase www.americanbankingnews.com - April 11 at 11:52 PM
	Regeneron (REGN) Upgraded to Strong-Buy by Zacks Investment Research www.americanbankingnews.com - April 11 at 6:44 PM
	Vertex Is Worth More Than You Think finance.yahoo.com - April 11 at 3:46 PM
	Zacks Investment Research Lowers Regeneron (REGN) to Hold www.americanbankingnews.com - April 11 at 1:48 PM
	Zacks: Analysts Anticipate Regeneron (REGN) Will Post Quarterly Sales of $1.54 Billion www.americanbankingnews.com - April 10 at 3:13 AM
	Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018 finance.yahoo.com - April 9 at 10:42 AM
	Regeneron (REGN) Rating Reiterated by Raymond James Financial www.americanbankingnews.com - April 9 at 8:51 AM
	Regeneron (REGN) Cut to Market Perform at UBS www.americanbankingnews.com - April 9 at 8:12 AM
	Regeneron (REGN) Expected to Post Earnings of $4.49 Per Share www.americanbankingnews.com - April 8 at 3:10 PM
	JPMorgan Chase Reiterates "Hold" Rating for Regeneron (REGN) www.americanbankingnews.com - April 6 at 9:50 PM
	Wired News – EMA to Review Regeneron’s Marketing Authorization Application for Cemiplimab finance.yahoo.com - April 5 at 8:09 AM
	Regeneron Pharmaceuticals Inc (REGN) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:34 PM
	Regeneron (REGN) & Sanofi (SNY) Report EMA to Review DUPIXENT (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma www.streetinsider.com - April 3 at 3:52 PM
	EMA Accepts Regeneron/Sanofi's application for Dupixent www.zacks.com - April 3 at 10:42 AM
	EMA accepts marketing application for Dupixent for asthma seekingalpha.com - April 3 at 10:42 AM
	Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label finance.yahoo.com - April 3 at 10:42 AM
	Regeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap finance.yahoo.com - April 2 at 10:53 AM
	Regeneron Pharmaceuticals (REGN) Given "Buy" Rating at Citigroup www.americanbankingnews.com - March 31 at 8:16 PM
	Regeneron Pharmaceuticals' (REGN) "Sector Perform" Rating Reiterated at Royal Bank of Canada www.americanbankingnews.com - March 31 at 6:06 PM
	A Post-4Q17 Update on Praluent’s Performance finance.yahoo.com - March 30 at 3:44 PM
	How Regeneron Pharmaceuticals’ Eylea Performed in 4Q17 and 2017 finance.yahoo.com - March 30 at 10:24 AM
	Citigroup Reiterates "Neutral" Rating for Regeneron Pharmaceuticals (REGN) www.americanbankingnews.com - March 29 at 11:52 PM
	BidaskClub Upgrades Regeneron Pharmaceuticals (REGN) to "Hold" www.americanbankingnews.com - March 29 at 11:28 AM
	BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod finance.yahoo.com - March 29 at 10:52 AM
	Regeneron CEO: There are structural issues around drug pr... finance.yahoo.com - March 28 at 3:41 PM
	Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) A Sell At Its Current PE Ratio? finance.yahoo.com - March 27 at 3:52 PM
	$1.54 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter www.americanbankingnews.com - March 24 at 4:49 AM
	Alnylam and Regeneron team up in NASH - Seeking Alpha seekingalpha.com - March 23 at 6:25 PM
	Regeneron (REGN) Genetics Center Publication in NEJM Identifies New Genetic Variant Providing Protection from Chronic Liver Disease www.streetinsider.com - March 23 at 9:52 AM
	Regeneron Collaborates With Alnylam to Develop NASH Treatment finance.yahoo.com - March 22 at 3:58 PM
	Powerhouse Duo Takes On Gilead, Allergan In Liver Disease, But Stocks Dip finance.yahoo.com - March 22 at 3:58 PM
	Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval finance.yahoo.com - March 22 at 3:58 PM
	Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead? finance.yahoo.com - March 22 at 3:58 PM
	FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY ... - Nasdaq www.nasdaq.com - March 22 at 10:12 AM
	Regeneron (REGN) Genetics Center Publication in NEJM Identifies ... - StreetInsider.com www.streetinsider.com - March 22 at 10:12 AM
	GlaxoSmithKline Initiates Phase III Combo Study on Benlysta finance.yahoo.com - March 21 at 3:57 PM

Regeneron (NASDAQ:REGN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Regeneron (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement

Regeneron (NASDAQ REGN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff